

(REVISED formerly DE-61)

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-44)

SOMAPACITAN

PRONUNCIATION

soe" ma pas' i tan

THERAPEUTIC CLAIM

Treatment of growth hormone deficiency

CHEMICAL NAMES

1. Somatotropin [101-cysteine] (human), (101→4')-thioether with *N*-[14,14-dioxido-1,10,16-trioxo-31-(1*H*-tetrazol-5-yl)-3,6-dioxa-14-thia-9,15-diazahentriacont-1-yl]-L-γ-glutamyl-L-γ-glutamyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-*N*^δ-(2-mercaptoacetyl)-L-lysine
2. [101-{*S*-[(8*S*,22*S*,27*S*)-8,22,27-tricarboxy-2,10,19,24,29,38,42,42,44-nonaoxo-59-(1*H*-tetrazol-5-yl)-12,15,31,34-tetraoxa-42-λ⁶-thia-3,9,18,23,28,37,43-heptaazanonapentacontyl]-L-cysteine}]human somatotropin

STRUCTURAL FORMULA


Sequence

FPTIPLSRLF	DNAMLRAHRL	HQLAFDTYQE	FEEAYIPKEQ	KYSFLQNPQT	50
SLCFSESIPT	PSNREETQOK	SNLELLRISL	LLIQSWLEPV	QFLRSVFANS	100
<u>C</u> VYGASDSNV	YDLLKDLEEG	IQTLMGRLED	GSPRTGQIFK	QTYSKFDTNS	150
HND DALLKNY	GLLYCFRKDM	DKVETFLRIV	QCRSVEGSCG	F	191

Disulfide bridges

53-165 182-189

Modified residues



MOLECULAR FORMULA

$\text{C}_{1038}\text{H}_{1609}\text{N}_{273}\text{O}_{319}\text{S}_9$

MOLECULAR WEIGHT

23.31 kDa

TRADEMARK

None as yet

SPONSOR

Novo Nordisk A/S

CODE DESIGNATIONS

NNC0195-0092, NN8640

CAS REGISTRY NUMBER 1338578-34-9

UNII 8FOJ430U94

WHO NUMBER 10019

gbk